Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact...

Full description

Bibliographic Details
Main Authors: Daphne W. Dumoulin, Robin Cornelissen, Koen Bezemer, Sara J. Baart, Joachim G. J. V. Aerts
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/9/5/525